Abstract
Purpose: To explore effects of atorvastatin in combination with probucol on blood lipid and serum Creactive protein of patients with cerebral infarction.Methods: In total, 120 patients with confirmed cerebral infarction were randomly divided into test and control groups (n = 60 each). Control group was given atorvastatin 20 mg, once every night, while test group received 0.5 g probucol twice daily plus atorvastatin 20 mg nightly. The treatment for both groups lasted for six months. Changes in carotid intima media thickness (CIMT), plaque area, vulnerability, high-sensitivity C-reactive protein level (hs-CRP) and low density lipoprotein (LDL) were observed before and after treatment and compared between groups. In 6-month follow up, incidence of newly occurred or reoccurred cerebral ischemic stroke were observed and compared between groups. Occurrence of severe untoward reaction was also noted.Results: In test group, LDL level significantly decreased after treatment, (p < 0.01), and when compared to control group (p < 0.05). CIMT, plaque area and number of vulnerable plaque after treatment were significantly different compared to the values prior to treatment and control group (p < 0.05). Incidence of cerebral ischemic stroke was similarly lower for the test group than control after treatment (p < 0.05). Both groups did not develop any severe untoward reaction.Conclusion: Atorvastatin, in combination with probucol, can be used to regulate blood lipid, lower LDL level, reduce number of vulnerable plaque, stabilize and reverse plaque, and lower risk of cerebral ischemic stroke of carotid atherosclerostic plaque. This work provides a theoretical basis and intervention measure for preventing ischemic stroke.Keywords: Probucol, Atorvastatin, C-reactive protein, Cerebral infarction, Carotid plaque, Blood lipid
Highlights
Cerebral infarction with high incidence rate, mortality rate, recurrence rate and disability rate is more likely to happen in middle aged and elderly people; it has been the primary cause for long-term disability of middle aged and elderly people worldwide, and the second cause leading to death in China [1]
In 2014, Hao et al [3] have proved that atorvastatin combined with probucol does improve adiponectin level of cerebral infraction patients and lower high-sensitivity C-reactive protein level, which is beneficial to stabilize atherosclerotic plaque and control the occurrence of cerebral infarction
Stability of carotid atherosclerostic plaque is considered to be closely correlated to the occurrence of cerebral infarction [9]; treatment of atherosclerotic lesion and stable plaque focuses on lipid regulation, oxidation resistance, anti-inflammation, platelet resistance and improvement of endothelial function [10]
Summary
Cerebral infarction with high incidence rate, mortality rate, recurrence rate and disability rate is more likely to happen in middle aged and elderly people; it has been the primary cause for long-term disability of middle aged and elderly people worldwide, and the second cause leading to death in China [1].Carotid atherosclerostic plaque is considered as the primary cause of the occurrence of cerebral infarction [2]. In 2014, Hao et al [3] have proved that atorvastatin combined with probucol does improve adiponectin level of cerebral infraction patients and lower high-sensitivity C-reactive protein (hs-CRP) level, which is beneficial to stabilize atherosclerotic plaque and control the occurrence of cerebral infarction. Zhang [4] pointed out that probucol combined with statin was effective in resisting inflammation and improving the level of adiponectin in the treatment of acute myocardial infarction (AMI), thereby protecting angiocarpy. Gao et al [5] found that, statins could effectively control and lower CRP level and blood lipid, reduce inflammation and eliminate carotid atherosclerostic plaque; and atorvastatin could reduce carotid intima media thickness (CIMT) while being used in secondary prevention
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
